Literature DB >> 6534031

The carboxyterminus of the hemagglutinin-neuraminidase of Newcastle disease virus is exposed at the surface of the viral envelope.

W Schuy, W Garten, D Linder, H D Klenk.   

Abstract

The amino-terminal and the carboxy-terminal amino acids of the hemagglutinin-neuraminidase glycoprotein of the Ulster strain of Newcastle disease virus have been analyzed before and after proteolytic activation of the precursor HNo (Mr approximately 82K). The amino termini of HNo and of the large cleavage fragment HN (approximately 74K) obtained by in vivo and in vitro proteolysis could not be sequenced by Edman degradation. This indicates that in both instances the amino termini are blocked. The carboxy termini of HNo and HN are different as demonstrated by end-point digestion with carboxypeptidase A. Furthermore, a small cleavage fragment (approximately 9K) of HNo that was removed from the virion after trypsin treatment could be purified by HPLC. In contrast to HN, this fragment displays a free amino terminus susceptible to Edman degradation. These data indicate that conversion of HNo involves removal of a 9K glycopeptide from the carboxy-terminal end. Thus, it has to be concluded that, unlike most other viral glycoproteins, the hemagglutinin-neuraminidase is inserted in the envelope with its carboxy terminus exposed at the surface of the virus particle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6534031     DOI: 10.1016/0168-1702(84)90027-3

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  23 in total

1.  Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition.

Authors:  R M Iorio; R J Syddall; J P Sheehan; M A Bratt; R L Glickman; A M Riel
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  The haemagglutinin-neuraminidase glycoprotein of the porcine paramyxovirus LPMV: comparison with other paramyxoviruses revealed the closest relationship to simian virus 5 and mumps virus.

Authors:  A Sundqvist; M Berg; J Moreno-López; T Linné
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Drastic immunoreactivity changes between the immature and mature forms of the Sendai virus HN and F0 glycoproteins.

Authors:  G Mottet; A Portner; L Roux
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Translation and membrane insertion of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.

Authors:  C Wilson; R Gilmore; T Morrison
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

5.  Hemagglutinin-neuraminidase protein of the paramyxovirus simian virus 5: nucleotide sequence of the mRNA predicts an N-terminal membrane anchor.

Authors:  S W Hiebert; R G Paterson; R A Lamb
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

6.  Effects of the components of Newcastle disease virus on the structural order of lipid assemblies.

Authors:  V Z Neitchev; L P Dumanova
Journal:  Mol Biol Rep       Date:  1992-02       Impact factor: 2.316

7.  Respiratory syncytial virus envelope glycoprotein (G) has a novel structure.

Authors:  M Satake; J E Coligan; N Elango; E Norrby; S Venkatesan
Journal:  Nucleic Acids Res       Date:  1985-11-11       Impact factor: 16.971

8.  Comparison of Newcastle disease viruses isolated from cormorants in Canada and the USA in 1975, 1990 and 1992.

Authors:  R A Heckert; M S Collins; R J Manvell; I Strong; J E Pearson; D J Alexander
Journal:  Can J Vet Res       Date:  1996-01       Impact factor: 1.310

9.  Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus.

Authors:  Aruna Panda; Subbiah Elankumaran; Sateesh Krishnamurthy; Zhuhui Huang; Siba K Samal
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies.

Authors:  M N Waxham; D C Merz; J S Wolinsky
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.